GTSM:4162

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer diseases in Taiwan and Europe. More Details


Snowflake Analysis

Flawless balance sheet with high growth potential.

Share Price & News

How has PharmaEngine's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 4162 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: 4162's weekly volatility (4%) has been stable over the past year.


Market Performance


7 Day Return

-8.9%

4162

-2.3%

TW Biotechs

-0.2%

TW Market


1 Year Return

-20.2%

4162

21.7%

TW Biotechs

28.6%

TW Market

Return vs Industry: 4162 underperformed the TW Biotechs industry which returned 21.7% over the past year.

Return vs Market: 4162 underperformed the TW Market which returned 28.6% over the past year.


Shareholder returns

4162IndustryMarket
7 Day-8.9%-2.3%-0.2%
30 Day-17.9%-7.8%8.8%
90 Day-14.5%-2.8%20.6%
1 Year-19.6%-20.2%22.2%21.7%33.1%28.6%
3 Year-65.9%-67.1%-17.7%-19.2%55.3%37.8%
5 Year-67.0%-68.8%-48.1%-48.6%135.7%94.2%

Long-Term Price Volatility Vs. Market

How volatile is PharmaEngine's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is PharmaEngine undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 4162 (NT$49.65) is trading below our estimate of fair value (NT$271.23)

Significantly Below Fair Value: 4162 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 4162 is poor value based on its PE Ratio (162x) compared to the TW Biotechs industry average (39.5x).

PE vs Market: 4162 is poor value based on its PE Ratio (162x) compared to the TW market (18.4x).


Price to Earnings Growth Ratio

PEG Ratio: 4162 is poor value based on its PEG Ratio (1.9x)


Price to Book Ratio

PB vs Industry: 4162 is good value based on its PB Ratio (2.1x) compared to the TW Biotechs industry average (4.8x).


Next Steps

Future Growth

How is PharmaEngine forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

85.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 4162's forecast earnings growth (85.1% per year) is above the savings rate (0.8%).

Earnings vs Market: 4162's earnings (85.1% per year) are forecast to grow faster than the TW market (18.7% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 4162's revenue (65.5% per year) is forecast to grow faster than the TW market (11.1% per year).

High Growth Revenue: 4162's revenue (65.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 4162's Return on Equity is forecast to be low in 3 years time (11.6%).


Next Steps

Past Performance

How has PharmaEngine performed over the past 5 years?

-23.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 4162 has a high level of non-cash earnings.

Growing Profit Margin: 4162's current net profit margins (13%) are lower than last year (35.6%).


Past Earnings Growth Analysis

Earnings Trend: 4162's earnings have declined by 23.9% per year over the past 5 years.

Accelerating Growth: 4162's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 4162 had negative earnings growth (-60.5%) over the past year, making it difficult to compare to the Biotechs industry average (-42.4%).


Return on Equity

High ROE: 4162's Return on Equity (1.3%) is considered low.


Next Steps

Financial Health

How is PharmaEngine's financial position?


Financial Position Analysis

Short Term Liabilities: 4162's short term assets (NT$3.6B) exceed its short term liabilities (NT$125.0M).

Long Term Liabilities: 4162's short term assets (NT$3.6B) exceed its long term liabilities (NT$13.7M).


Debt to Equity History and Analysis

Debt Level: 4162 is debt free.

Reducing Debt: 4162 has not had any debt for past 5 years.

Debt Coverage: 4162 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 4162 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is PharmaEngine current dividend yield, its reliability and sustainability?

1.01%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 4162's dividend (1.01%) isn’t notable compared to the bottom 25% of dividend payers in the TW market (2.13%).

High Dividend: 4162's dividend (1.01%) is low compared to the top 25% of dividend payers in the TW market (5.17%).


Stability and Growth of Payments

Stable Dividend: 4162 is not paying a notable dividend for the TW market, therefore no need to check if payments are stable.

Growing Dividend: 4162 is not paying a notable dividend for the TW market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: 4162 is not paying a notable dividend for the TW market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 4162's dividend in 3 years as they are not forecast to pay a notable one for the TW market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.0yrs

Average management tenure


CEO

Yufang Hu

1.58yrs

Tenure

NT$4,092,000

Compensation

Dr. Hu Yufang, Ph.D, R.Ph, is President of PharmaEngine, Inc. He is a registered pharmacist as well. Before coming back to Taiwan, he had worked for the Bristol-Myers Squibb Pharmaceutical Company (New Jer...


CEO Compensation Analysis

Compensation vs Market: Yufang's total compensation ($USD146.18K) is about average for companies of similar size in the TW market ($USD167.57K).

Compensation vs Earnings: Insufficient data to compare Yufang's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Yufang Hu
President1.58yrsNT$4.09mno data
Chi-Hsing Chang
Vice President of Finance & Administration7yrsNT$4.66mno data
C. Chan
Vice President of Clinical & Regulatory Affairs4.92yrsNT$6.85mno data
De Cheng Tu
Chairman of the Board1yrno datano data
Jose Hsieh
Senior Manager of Accountingno datano datano data
Peter Wu
Senior Director of Marketing & Sales4yrsno datano data
Melody Lin
Director of Human Resourcesno datano datano data

4.0yrs

Average Tenure

Experienced Management: 4162's management team is considered experienced (4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
De Cheng Tu
Chairman of the Board1yrno datano data
Jin-Rong Lin
Director3yrsNT$292.00kno data
Rui-Wen Wu
Director3yrsNT$287.00kno data
Yi-Hui Lin
Director2.67yrsNT$311.00kno data
Chi-Ying Huang
Director1.58yrsNT$236.00kno data
Sonny Wang
Independent Director1.58yrsNT$945.00kno data
Yu-Ching Su
Independent Director1.58yrsNT$987.00kno data
Chih-Li Wang
Independent Director1.58yrsNT$987.00kno data

1.6yrs

Average Tenure

Experienced Board: 4162's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

PharmaEngine, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: PharmaEngine, Inc.
  • Ticker: 4162
  • Exchange: GTSM
  • Founded: 2002
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: NT$7.229b
  • Shares outstanding: 145.60m
  • Website: https://www.pharmaengine.com

Location

  • PharmaEngine, Inc.
  • 10 Minsheng East Road
  • 11th Floor
  • Taipei
  • 104
  • Taiwan

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
4162GTSM (Taipei Exchange)YesCommon StockTWTWDSep 2011

Biography

PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer diseases in Taiwan and Europe. It is developing ONIVYDE for patients with gemc...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/21 17:19
End of Day Share Price2021/01/21 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.